Abstract

Humoral immunity is critically important to control COVID-19. Long-term antibody responses remain to be fully characterized in hospitalized patients who have a high risk of death. We compared specific Immunoglobulin responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between two groups, intensive care unit (ICU) and non-ICU hospitalized patients over several weeks. Plasma specific IgG, IgM, and IgA levels were assessed using a commercial ELISA and compared to an in-house cell-based ELISA. Among the patients analyzed (mean (SD) of age, 64.4 (15.9) years, 19.2% female), 12 (46.2%) were hospitalized in ICU. IgG levels increased in non-ICU cases from the second to the eighth week after symptom onset. By contrast, IgG response was blunted in ICU patients over the same period. ICU patients with hematological malignancies had very weak or even undetectable IgG levels. While both groups had comparable levels of specific IgM antibodies, we found much lower levels of specific IgA in ICU versus non-ICU patients. In conclusion, COVID-19 ICU patients may be at risk of reinfection as their specific IgG response is declining in a matter of weeks. Antibody neutralizing assays and studies on specific cellular immunity will have to be performed.

Highlights

  • According to the World Health Organization (WHO), the coronavirus disease 2019 (COVID-19) pandemic currently affects more than 48 million individuals worldwide

  • Up to 10–15% of hospitalized patients progress to a severe form of the disease and may develop pneumonia, acute respiratory distress syndrome, and multiple organ failure, requiring long stays in intensive care units (ICU) [1,2,3]

  • Long-term antibody responses remain to be fully characterized, in hospitalized patients, and for instance, for those transferred to ICU and with very poor prognosis

Read more

Summary

Introduction

According to the World Health Organization (WHO), the coronavirus disease 2019 (COVID-19) pandemic currently affects more than 48 million individuals (confirmed cases) worldwide. The kinetics of the humoral response was recently described in symptomatic (non-severe) and convalescent COVID-19 individuals and revealed that antibody levels against the receptor binding domain (RBD) of SARS-CoV-2 decline over time [7,8,9,10]. Despite these findings, long-term antibody responses remain to be fully characterized, in hospitalized patients, and for instance, for those transferred to ICU and with very poor prognosis. We described serological results using a commercial and a robust conventional in-house cell-based ELISA for the detection of anti-SARS-CoV-2 Ig and assessed the evolution of Ig plasma levels over a two-month period in patients hospitalized in ICU versus non-ICU hospitalized cases

Ethical Statement
Study Design and Participants
Statistical Analyses
Findings
Kinetics of anti-SARS-CoV-2 IgG Response in non-ICU and ICU Patients
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call